Clinical Trial: Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC

U.S., April 2 -- ClinicalTrials.gov registry received information related to the study (NCT06904196) titled 'Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC' on March 25.

Brief Summary: This study is conducted to evaluate the efficacy and safety of lenvatinib plus SIRT (LEN+SIRT) compared with lenvatinib (LEN) alone for patients with hepatocellular carcinoma (HCC) refractory to transarterial chemoembolization (TACE).

Study Start Date: April 01

Study Type: INTERVENTIONAL

Condition: Hepatocellular Carcinoma Non-resectable

Intervention: COMBINATION_PRODUCT: Lenvatinib plus SIRT

Lenvatinib 12mg (body weight >=60kg) or 8mg (body weight =60kg) or 8mg (body weight <60kg) P.O. QD.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: ...